Overview

A Phase /a Study of SNUG01 in Adult Subjects With ALS

Status:
NOT_YET_RECRUITING
Trial end date:
2028-09-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy of SNUG01 in in adult subjects with Amyotrophic Lateral Sclerosis (ALS).
Phase:
PHASE1
Details
Lead Sponsor:
SineuGene Therapeutics Co., Ltd.